News

Innomar Strategies announced the acquisition of regulatory consulting firm Therapeutic Products Inc. (TPIreg). With the addition of TPIreg, Innomar is the first full service distributor…
Read More...

AGC Biologics announced it has entered into an agreement with Horizon Pharma plc for commercial supply of teprotumumab, a monoclonal antibody biologic for the treatment of…
Read More...

Novartis announced that the US Food and Drug Administration (FDA) has approved Tafinlar (dabrafenib) in combination with Mekinist (trametinib) for the adjuvant treatment of patients…
Read More...

AbbVie announced that it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for risankizumab, an investigational interleukin-23 (IL-23)…
Read More...

Bavarian Nordic A/S announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company’s novel cancer vaccine BN-Brachyury for the treatment…
Read More...

Merck KGaA, Darmstadt, Germany announced a development agreement for investigational molecule abituzumab with SFJ Pharmaceuticals Group (SFJ), a US-based company focused on increasing…
Read More...

Haselmeier, a Swiss-based developer and manufacturer of innovative self-injection devices, and Common Sensing, a Cambridge-based smart injector monitoring and support solutions company,…
Read More...

Janssen Biotech announced that it has entered into a definitive agreement under which it will acquire BeneVir Biopharm, Inc. (BeneVir), a privately-held, biopharmaceutical company…
Read More...

Cirius Therapeutics announced that it has reached its enrollment target in its Phase 2b EMMINENCE trial for its lead program MSDC-0602K in more than 380 patients with NASH and liver…
Read More...

OnKure, Inc., the epigenetics-focused drug discovery and development company that is advancing the first Largazole-derived, histone deacetylase inhibitor into Phase 1 clinical trials,…
Read More...

ACADIA Pharmaceuticals Inc. announced that Elena Ridloff, CFA, has been appointed to the newly created position of Senior Vice President, Investor Relations, leading investor and…
Read More...

Exelixis announced that it has entered into a collaboration with Invenra, Inc., the Madison, Wisconsin-based biotechnology firm focused on developing next-generation biologics, to…
Read More...

Bactevo Ltd. announced that it has entered into a drug discovery collaboration agreement with Boehringer Ingelheim to identify novel small molecule lead compounds. This collaboration…
Read More...

Upsher-Smith Laboratories, LLC (Upsher-Smith) announced the launch of Doxazosin Tablets, USP, 1 mg, 2 mg, 4 mg and 8 mg. The product was approved by the U.S. Food and Drug…
Read More...

Bioniz Therapeutics announced top-line results from its multiple ascending dose Phase 1b clinical trial of BNZ-1, a novel multi-cytokine inhibitor targeting interleukin (IL)-2, IL-9,…
Read More...

Biogen and Neurimmune announced that Biogen has exercised its option to further reduce the previously negotiated royalty rates payable on potential future sales of aducanumab, Biogen’s…
Read More...

Novartis announced the launch of its FocalView app, an ophthalmic digital research platform created with ResearchKit. FocalView aims to allow researchers to track disease progression by…
Read More...

AbbVie announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration for risankizumab, an investigational interleukin-23 (IL-23)…
Read More...

Concert Pharmaceuticals announced that it has completed patient enrollment of its Phase 2a trial evaluating CTP-543 for the treatment of moderate-to-severe alopecia areata. The Company…
Read More...

Immune Therapeutics announced that the Kenya Pharmacy and Poison Board filed IMUN’s New Drug Application (NDA) for Lodonal, its lead drug candidate, thereby accepting the NDA for a full…
Read More...